Gene therapy for infantile malignant osteopetrosis: review of pre-clinical research and proof-of-concept for phenotypic reversal
Infantile malignant osteopetrosis is a devastating disorder of early childhood that is frequently fatal and for which there are only limited therapeutic options. Gene therapy utilizing autologous hematopoietic stem and progenitor cells represents a potentially advantageous therapeutic alternative fo...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-03-01
|
Series: | Molecular Therapy: Methods & Clinical Development |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2329050120302576 |
id |
doaj-c0603ecb4f8d4f5388fd9fa854ead6c3 |
---|---|
record_format |
Article |
spelling |
doaj-c0603ecb4f8d4f5388fd9fa854ead6c32021-03-13T04:23:44ZengElsevierMolecular Therapy: Methods & Clinical Development2329-05012021-03-0120389397Gene therapy for infantile malignant osteopetrosis: review of pre-clinical research and proof-of-concept for phenotypic reversalIlana Moscatelli0Elena Almarza1Axel Schambach2David Ricks3Ansgar Schulz4Christopher D. Herzog5Kim Henriksen6Maria Askmyr7Jonathan D. Schwartz8Johan Richter9Department of Molecular Medicine and Gene Therapy, Lund Strategic Center for Stem Cell Biology, Lund University, Lund, Sweden; Corresponding author: Ilana Moscatelli, Department of Molecular Medicine and Gene Therapy, Lund Strategic Center for Stem Cell Biology, Lund University, Lund, Sweden.Rocket Pharmaceuticals, Inc., New York, NY, USAInstitute of Experimental Hematology, Hannover Medical School, Hannover, Germany; Division of Hematology/Oncology, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USARocket Pharmaceuticals, Inc., New York, NY, USADepartment of Pediatrics and Adolescent Medicine, University Medical Center Ulm, GermanyRocket Pharmaceuticals, Inc., New York, NY, USANordic Bioscience A/S, Herlev, DenmarkDepartment of Molecular Medicine and Gene Therapy, Lund Strategic Center for Stem Cell Biology, Lund University, Lund, SwedenRocket Pharmaceuticals, Inc., New York, NY, USADepartment of Molecular Medicine and Gene Therapy, Lund Strategic Center for Stem Cell Biology, Lund University, Lund, SwedenInfantile malignant osteopetrosis is a devastating disorder of early childhood that is frequently fatal and for which there are only limited therapeutic options. Gene therapy utilizing autologous hematopoietic stem and progenitor cells represents a potentially advantageous therapeutic alternative for this multisystemic disease. Gene therapy can be performed relatively rapidly following diagnosis, will not result in graft versus host disease, and may also have potential for reduced incidences of other transplant-related complications. In this review, we have summarized the past sixteen years of research aimed at developing a gene therapy for infantile malignant osteopetrosis; these efforts have culminated in the first clinical trial employing lentiviral-mediated delivery of TCIRG1 in autologous hematopoietic stem and progenitor cells.http://www.sciencedirect.com/science/article/pii/S2329050120302576infantile malignant osteopetrosislentivirusgene therapyautosomal recessive osteopetrosishematopoietic stem and progenitor cellsosteoclast disorders |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ilana Moscatelli Elena Almarza Axel Schambach David Ricks Ansgar Schulz Christopher D. Herzog Kim Henriksen Maria Askmyr Jonathan D. Schwartz Johan Richter |
spellingShingle |
Ilana Moscatelli Elena Almarza Axel Schambach David Ricks Ansgar Schulz Christopher D. Herzog Kim Henriksen Maria Askmyr Jonathan D. Schwartz Johan Richter Gene therapy for infantile malignant osteopetrosis: review of pre-clinical research and proof-of-concept for phenotypic reversal Molecular Therapy: Methods & Clinical Development infantile malignant osteopetrosis lentivirus gene therapy autosomal recessive osteopetrosis hematopoietic stem and progenitor cells osteoclast disorders |
author_facet |
Ilana Moscatelli Elena Almarza Axel Schambach David Ricks Ansgar Schulz Christopher D. Herzog Kim Henriksen Maria Askmyr Jonathan D. Schwartz Johan Richter |
author_sort |
Ilana Moscatelli |
title |
Gene therapy for infantile malignant osteopetrosis: review of pre-clinical research and proof-of-concept for phenotypic reversal |
title_short |
Gene therapy for infantile malignant osteopetrosis: review of pre-clinical research and proof-of-concept for phenotypic reversal |
title_full |
Gene therapy for infantile malignant osteopetrosis: review of pre-clinical research and proof-of-concept for phenotypic reversal |
title_fullStr |
Gene therapy for infantile malignant osteopetrosis: review of pre-clinical research and proof-of-concept for phenotypic reversal |
title_full_unstemmed |
Gene therapy for infantile malignant osteopetrosis: review of pre-clinical research and proof-of-concept for phenotypic reversal |
title_sort |
gene therapy for infantile malignant osteopetrosis: review of pre-clinical research and proof-of-concept for phenotypic reversal |
publisher |
Elsevier |
series |
Molecular Therapy: Methods & Clinical Development |
issn |
2329-0501 |
publishDate |
2021-03-01 |
description |
Infantile malignant osteopetrosis is a devastating disorder of early childhood that is frequently fatal and for which there are only limited therapeutic options. Gene therapy utilizing autologous hematopoietic stem and progenitor cells represents a potentially advantageous therapeutic alternative for this multisystemic disease. Gene therapy can be performed relatively rapidly following diagnosis, will not result in graft versus host disease, and may also have potential for reduced incidences of other transplant-related complications. In this review, we have summarized the past sixteen years of research aimed at developing a gene therapy for infantile malignant osteopetrosis; these efforts have culminated in the first clinical trial employing lentiviral-mediated delivery of TCIRG1 in autologous hematopoietic stem and progenitor cells. |
topic |
infantile malignant osteopetrosis lentivirus gene therapy autosomal recessive osteopetrosis hematopoietic stem and progenitor cells osteoclast disorders |
url |
http://www.sciencedirect.com/science/article/pii/S2329050120302576 |
work_keys_str_mv |
AT ilanamoscatelli genetherapyforinfantilemalignantosteopetrosisreviewofpreclinicalresearchandproofofconceptforphenotypicreversal AT elenaalmarza genetherapyforinfantilemalignantosteopetrosisreviewofpreclinicalresearchandproofofconceptforphenotypicreversal AT axelschambach genetherapyforinfantilemalignantosteopetrosisreviewofpreclinicalresearchandproofofconceptforphenotypicreversal AT davidricks genetherapyforinfantilemalignantosteopetrosisreviewofpreclinicalresearchandproofofconceptforphenotypicreversal AT ansgarschulz genetherapyforinfantilemalignantosteopetrosisreviewofpreclinicalresearchandproofofconceptforphenotypicreversal AT christopherdherzog genetherapyforinfantilemalignantosteopetrosisreviewofpreclinicalresearchandproofofconceptforphenotypicreversal AT kimhenriksen genetherapyforinfantilemalignantosteopetrosisreviewofpreclinicalresearchandproofofconceptforphenotypicreversal AT mariaaskmyr genetherapyforinfantilemalignantosteopetrosisreviewofpreclinicalresearchandproofofconceptforphenotypicreversal AT jonathandschwartz genetherapyforinfantilemalignantosteopetrosisreviewofpreclinicalresearchandproofofconceptforphenotypicreversal AT johanrichter genetherapyforinfantilemalignantosteopetrosisreviewofpreclinicalresearchandproofofconceptforphenotypicreversal |
_version_ |
1724222208510787584 |